Bifidobacterium infantis NLS super strain (B. infantis NLS-SS) was previously shown to alleviate gastrointestinal symptoms in newly diagnosed coeliac disease (CD) patients consuming gluten. A high proportion of patients following a gluten-free diet experiences symptoms despite dietary compliance. The role of B. infantis in persistently symptomatic CD patients has not been explored. The aim of the study was to evaluate the effect of B. infantis NLS-SS on persistent gastrointestinal symptoms in patients with CD following a long-term GFD. We conducted a randomised, cross-over, double-blind, placebo-controlled trial in symptomatic adult CD patients on a GFD for at least two years. After one-week run-in, patients were randomised to B. infantis NLS-SS or placebo for 3 weeks with cross-over after a 2-week wash-out period. We estimated changes (Δ) in celiac symptom index (CSI) before and after treatment. Stool samples were collected for faecal microbiota analysis (16S rRNA sequencing). Gluten immunogenic peptide (GIP) excretion in stool and urine samples was measured at each study period. Eighteen patients were enrolled; six patients were excluded due violations in protocol. For patients with the highest clinical burden, CD symptoms were lower in probiotic than in placebo treatment (P=0.046). B. infantis and placebo treated groups had different microbiota profiles as assessed by beta diversity clustering. In probiotic treated groups, we observed an increase in abundance of B. infantis. Treatment with B. infantis was associated with decreased abundance of Ruminococcus sp. and Bifidobacterium adolescentis. GIP excretion in stools and urine was similar at each treatment period. There were no differences in adverse effects between the two groups. B. infantis NLS-SS improves specific CD symptoms in a subset of highly symptomatic treated patients (GFD). This is associated with a shift in stool microbiota profile. Larger studies are needed to confirm these findings. ClinicalTrials.gov: NCT03271138
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J. and Holmes, S.P., 2016. DADA2: high-resolution sample inference from Illumina amplicon data. Nature Methods: 13: 581-583.
'DADA2: high-resolution sample inference from Illumina amplicon data ' () 13 Nature Methods : 581 -583.
Caminero, A. and Verdu, E.F., 2019a. Celiac disease: should we care about microbes? American Journal Physiology – Gastrointestinal Liver Physiology 317: G161-G170.
'Celiac disease: should we care about microbes? ' () 317 American Journal Physiology – Gastrointestinal Liver Physiology : G161 -G170.
Caminero, A. and Verdu, E.F., 2019b. Metabolism of wheat proteins by intestinal microbes: implications for wheat related disorders. Gastroenterología y Hepatología (English edition) 42: 449-457.
'Metabolism of wheat proteins by intestinal microbes: implications for wheat related disorders ' () 42 Gastroenterología y Hepatología (English edition) : 449 -457.
Caminero, A., McCarville, J.L., Galipeau, H.J., Deraison, C., Bernier, S.P., Constante, M., Rolland, C., Meisel, M., Murray, J.A., Yu, X.B., Alaedini, A., Coombes, B.K., Bercik, P., Southward, C.M., Ruf, W., Jabri, B., Chirdo, F.G., Casqueiro, J., Surette, M.G., Vergnolle, N. and Verdu, E.F., 2019a. Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2. Nature Communications 13: 1198.
'Duodenal bacterial proteolytic activity determines sensitivity to dietary antigen through protease-activated receptor-2 ' () 13 Nature Communications : 1198.
Caminero, A., McCarville, J.L., Zevallos, V.F., Pigrau, M., Yu, X.B., Jury, J., Galipeau, H.J., Clarizio, A.V., Casqueiro, J., Murray, J.A., Collins, S.M., Alaedini, A., Bercik, P., Schuppan, D. and Verdu, E.F., 2019b. Lactobacilli degrade wheat amylase trypsin inhibitors to reduce intestinal dysfunction induced by immunogenic wheat proteins. Gastroenterology 156: 2266-2280.
'Lactobacilli degrade wheat amylase trypsin inhibitors to reduce intestinal dysfunction induced by immunogenic wheat proteins ' () 156 Gastroenterology : 2266 -2280.
Collado, M.C., Donat, E., Ribes-Koninckx, C., Calabuig, M. and Sanz, Y., 2008. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiology 22: 232.
'Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease ' () 22 BMC Microbiology : 232.
Costa, A.F., Sugai, E., Temprano, M.P., Niveloni, S.I., Vázquez, H., Moreno, M.L., Domínguez-Flores, M.R., Muñoz-Suano, A., Smecuol, E., Stefanolo, J.P., González, A.F., Cebolla-Ramirez, A., Mauriño, E., Verdú, E.F. and Bai, J.C., 2019. Gluten immunogenic peptide detects dietary transgressions in treated celiac disease patients. Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients. World Journal of Gastroenterology 25: 1409-1420.
'Gluten immunogenic peptide detects dietary transgressions in treated celiac disease patients ' () 25 World Journal of Gastroenterology : 1409 -1420.
De Palma, G., Collins, S.M. and Bercik, P., 2014. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes 5: 419-429.
'The microbiota-gut-brain axis in functional gastrointestinal disorders ' () 5 Gut Microbes : 419 -429.
Francavilla, R., Piccolo, M., Francavilla, A., Polimeno, L., Semeraro, F., Cristofori, F., Castellaneta, S., Barone, M., Indrio, F., Gobbetti, M. and De Angelis, M., 2019. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms. A randomized, double-blind, placebo-controlled, multicenter trial. Journal of Clinical Gastroenterology 53: e117-e125.
'Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms ' () 53 Journal of Clinical Gastroenterology : e117 -e125.
Fuhler, G.M. and Hecht, G.A., 2020. Gut microbiota for health world summit. Gastroenterology 158: 28-31.
'Gut microbiota for health world summit ' () 158 Gastroenterology : 28 -31.
Green, P.H. and Cellier, C., 2007. Celiac disease. New England Journal of Medicine 357: 1731-1743.
'Celiac disease ' () 357 New England Journal of Medicine : 1731 -1743.
Kelly, C.P., Bai, J.C., Liu, E. and Leffler, D., 2015. Advances in diagnosis and management of celiac disease. Gastroenterology 148: 1175-1186.
'Advances in diagnosis and management of celiac disease ' () 148 Gastroenterology : 1175 -1186.
Leffler, D.A., Dennis, M., Hyett, B., Kelly, E., Schuppan, D. and Kelly, C.P., 2007. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clinical Gastroenterology and Hepatology 5: 445-450.
'Etiologies and predictors of diagnosis in nonresponsive celiac disease ' () 5 Clinical Gastroenterology and Hepatology : 445 -450.
Leonard, M.M., Cureton, P. and Fasano, A., 2017. Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease. Nutrients 9: 1129.
'Indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease ' () 9 Nutrients : 1129.
Lindfors, K., Ciacci, C., Kurppa, K., Lundin, K.E.A., Makharia, G.K., Mearin, M.L., Murray, J.A., Verdu, E.F. and Kaukinen, K., 2019. Coeliac disease. Nature Review Disease Primers 5: 3.
'Coeliac disease ' () 5 Nature Review Disease Primers : 3.
McMurdie, P.J. and Holmes, S., 2013. Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8: e61217.
'Phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data ' () 8 PLoS ONE : e61217.
Olivares, M., Castillejo, G., Varea, V. and Sanz, Y., 2014. Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease. British Journal of Nutrition 112: 30-40.
'Double-blind, randomised, placebo-controlled intervention trial to evaluate the effects of Bifidobacterium longum CECT 7347 in children with newly diagnosed coeliac disease ' () 112 British Journal of Nutrition : 30 -40.
Penny, H.A., Baggus, E.M.R., Rej, A., Snowden, J.A. and Sanders, D.S., 2019. Non-responsive coeliac disease: a comprehensive review from the NHS England National Centre for refractory coeliac disease. Nutrients 12: 216.
'Non-responsive coeliac disease: a comprehensive review from the NHS England National Centre for refractory coeliac disease ' () 12 Nutrients : 216.
Pinto-Sanchez, M.I. and Verdu, E.F., 2018. Non-celiac gluten or wheat sensitivity: It’s complicated! Neurogastroenterology and Motility 30: e13392.
'Non-celiac gluten or wheat sensitivity: It’s complicated! ' () 30 Neurogastroenterology and Motility : e13392.
Pinto-Sánchez, M.I., Smecuol, E.C., Temprano, M.P., Sugai, E., González, A., Moreno, M.L., Huang, X., Bercik, P., Cabanne, A., Vázquez, H., Niveloni, S., Mazure, R., Mauriño, E., Verdú, E.F. and Bai, J.C., 2017. Bifidobacterium infantis NLS super strain reduces the expression of α-defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients. Journal of Clinical Gastroenterology 51: 814-817.
'Bifidobacterium infantis NLS super strain reduces the expression of α-defensin-5, a marker of innate immunity, in the mucosa of active celiac disease patients ' () 51 Journal of Clinical Gastroenterology : 814 -817.
Quagliariello, A., Aloisio, I., Bozzi Cionci, N., Luiselli, D., D’Auria, G., Martinez-Priego, L., Pérez-Villarroya, D., Langerholc, T., Primec, M., Micetic-Turk, D. and Di Gioia, D., 2016. Effect of Bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: a pilot study. Nutrients 8: 660.
'Effect of Bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: a pilot study ' () 8 Nutrients : 660.
Rubio-Tapia, A., Hill, I.D., Kelly, C.P., Calderwood, A.H. and Murray, J.A., 2013. American College of Gastroenterology. ACG clinical guidelines: diagnosis and management of celiac disease. American Journal of Gastroenterology 108: 656-676.
'American College of Gastroenterology ' () 108 American Journal of Gastroenterology : 656 -676.
Smecuol, E., Hwang, H.J., Sugai, E., Corso, L., Cherñavsky, A.C., Bellavite, F.P., González, A., Vodánovich, F., Moreno, M.L., Vázquez, H., Lozano, G., Niveloni, S., Mazure, R., Meddings, J., Mauriño, E. and Bai, J.C., 2013. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis Natren life start strain super strain in active celiac disease. Journal of Clinical Gastroenterology 47: 139-147.
'Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis Natren life start strain super strain in active celiac disease ' () 47 Journal of Clinical Gastroenterology : 139 -147.
Sugai, E., Moreno, M.L., Hwang, H.J., Cabanne, A., Crivelli, A., Nachman, F., Vázquez, H., Niveloni, S., Argonz, J., Mazure, R., La Motta, G., Caniggia, M.E., Smecuol, E., Chopita, N., Gómez, J.C., Mauriño, E. and Bai, J.C., 2010. Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? World Journal of Gastroenterology 16: 3144-3152.
'Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? ' () 16 World Journal of Gastroenterology : 3144 -3152.
Verdu, E.F., Galipeau, H.J. and Jabri, B., 2015. Novel players in coeliac disease pathogenesis: role of the gut microbiota. Nature Reviews Gastroenterology and Hepatology 12: 497-506.
'Novel players in coeliac disease pathogenesis: role of the gut microbiota ' () 12 Nature Reviews Gastroenterology and Hepatology : 497 -506.
Wacklin, P., Laurikka, P., Lindfors, K., Collin, P., Salmi, T., Lähdeaho, M.L., Saavalainen, P., Mäki, M., Mättö, J., Kurppa, K. and Kaukinen, K., 2014. Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet. American Journal of Gastroenterology 109: 1933-1941.
'Altered duodenal microbiota composition in celiac disease patients suffering from persistent symptoms on a long-term gluten-free diet ' () 109 American Journal of Gastroenterology : 1933 -1941.
All Time | Past 365 days | Past 30 Days | |
---|---|---|---|
Abstract Views | 1116 | 809 | 44 |
Full Text Views | 33 | 25 | 0 |
PDF Views & Downloads | 62 | 54 | 0 |
Bifidobacterium infantis NLS super strain (B. infantis NLS-SS) was previously shown to alleviate gastrointestinal symptoms in newly diagnosed coeliac disease (CD) patients consuming gluten. A high proportion of patients following a gluten-free diet experiences symptoms despite dietary compliance. The role of B. infantis in persistently symptomatic CD patients has not been explored. The aim of the study was to evaluate the effect of B. infantis NLS-SS on persistent gastrointestinal symptoms in patients with CD following a long-term GFD. We conducted a randomised, cross-over, double-blind, placebo-controlled trial in symptomatic adult CD patients on a GFD for at least two years. After one-week run-in, patients were randomised to B. infantis NLS-SS or placebo for 3 weeks with cross-over after a 2-week wash-out period. We estimated changes (Δ) in celiac symptom index (CSI) before and after treatment. Stool samples were collected for faecal microbiota analysis (16S rRNA sequencing). Gluten immunogenic peptide (GIP) excretion in stool and urine samples was measured at each study period. Eighteen patients were enrolled; six patients were excluded due violations in protocol. For patients with the highest clinical burden, CD symptoms were lower in probiotic than in placebo treatment (P=0.046). B. infantis and placebo treated groups had different microbiota profiles as assessed by beta diversity clustering. In probiotic treated groups, we observed an increase in abundance of B. infantis. Treatment with B. infantis was associated with decreased abundance of Ruminococcus sp. and Bifidobacterium adolescentis. GIP excretion in stools and urine was similar at each treatment period. There were no differences in adverse effects between the two groups. B. infantis NLS-SS improves specific CD symptoms in a subset of highly symptomatic treated patients (GFD). This is associated with a shift in stool microbiota profile. Larger studies are needed to confirm these findings. ClinicalTrials.gov: NCT03271138
All Time | Past 365 days | Past 30 Days | |
---|---|---|---|
Abstract Views | 1116 | 809 | 44 |
Full Text Views | 33 | 25 | 0 |
PDF Views & Downloads | 62 | 54 | 0 |